-
1
-
-
84897970506
-
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
-
Erratum in: Circulation 2014; 129:S46-S48
-
Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S1-S45. Erratum in: Circulation 2014; 129:S46-S48
-
(2014)
Circulation
, vol.129
, pp. S1-S45
-
-
Stone, N.J.1
Robinson, J.G.2
Lichtenstein, A.H.3
-
3
-
-
84924662763
-
A proposal to incorporate trial data into a hybrid ACC/AHA algorithm for the allocation of statin therapy in primary prevention
-
Ridker PM, Rose L, Cook NR. A proposal to incorporate trial data into a hybrid ACC/AHA algorithm for the allocation of statin therapy in primary prevention. J Am Coll Cardiol 2015; 65:942-948
-
(2015)
J Am Coll Cardiol
, vol.65
, pp. 942-948
-
-
Ridker, P.M.1
Rose, L.2
Cook, N.R.3
-
4
-
-
84934277268
-
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
-
Mega JL, Stitziel NO, Smith JG, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015; 385:2264-2271
-
(2015)
Lancet
, vol.385
, pp. 2264-2271
-
-
Mega, J.L.1
Stitziel, N.O.2
Smith, J.G.3
-
5
-
-
0027987849
-
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
-
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389
-
(1994)
Lancet
, vol.344
, pp. 1383-1389
-
-
-
6
-
-
11144355354
-
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
-
Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504
-
(2004)
N Engl J Med
, vol.350
, pp. 1495-1504
-
-
Cannon, C.P.1
Braunwald, E.2
McCabe, C.H.3
-
7
-
-
3142729178
-
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
-
Erratum in Circulation 2004; 110:763
-
Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239. Erratum in Circulation 2004; 110:763
-
(2004)
Circulation
, vol.110
, pp. 227-239
-
-
Grundy, S.M.1
Cleeman, J.I.2
Merz, C.N.3
-
8
-
-
56749106312
-
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
-
Ridker PM, Danielson E, Fonseca FAH, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207
-
(2008)
N Engl J Med
, vol.359
, pp. 2195-2207
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.H.3
-
9
-
-
0022549920
-
A receptor-mediated pathway for cholesterol homeostasis
-
Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232:34-47
-
(1986)
Science
, vol.232
, pp. 34-47
-
-
Brown, M.S.1
Goldstein, J.L.2
-
11
-
-
78449281377
-
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
-
Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670-1681
-
(2010)
Lancet
, vol.376
, pp. 1670-1681
-
-
Baigent, C.1
Blackwell, L.2
Emberson, J.3
-
12
-
-
79953836812
-
Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)
-
Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011; 57:1666-1675
-
(2011)
J Am Coll Cardiol
, vol.57
, pp. 1666-1675
-
-
Hsia, J.1
MacFadyen, J.G.2
Monyak, J.3
Ridker, P.M.4
-
13
-
-
50949102416
-
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
-
Cannon CP, Giugliano RP, Blazing MA, et al; IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008; 156:826-832
-
(2008)
Am Heart J
, vol.156
, pp. 826-832
-
-
Cannon, C.P.1
Giugliano, R.P.2
Blazing, M.A.3
-
14
-
-
84931411520
-
Ezetimibe added to statin therapy after acute coronary syndromes
-
Cannon CP, Blazing MA, Giugliano RP, et al for the IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372:2387-2397
-
(2015)
N Engl J Med
, vol.372
, pp. 2387-2397
-
-
Cannon, C.P.1
Blazing, M.A.2
Giugliano, R.P.3
-
15
-
-
84931033888
-
Are PCSK9 Inhibitors the next breakthrough in the cardiovascular field?
-
Giugliano RP, Sabatine MS. Are PCSK9 Inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiol 2015; 65:2638-2651
-
(2015)
J Am Coll Cardiol
, vol.65
, pp. 2638-2651
-
-
Giugliano, R.P.1
Sabatine, M.S.2
-
16
-
-
33645103550
-
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
-
Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264-1272
-
(2006)
N Engl J Med
, vol.354
, pp. 1264-1272
-
-
Cohen, J.C.1
Boerwinkle, E.2
Mosley, T.H.3
Hobbs, H.H.4
-
17
-
-
33748661502
-
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
-
Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006; 79:514-523
-
(2006)
Am J Hum Genet
, vol.79
, pp. 514-523
-
-
Zhao, Z.1
Tuakli-Wosornu, Y.2
Lagace, T.A.3
-
18
-
-
34447299120
-
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
-
Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007; 193:445-448
-
(2007)
Atherosclerosis
, vol.193
, pp. 445-448
-
-
Hooper, A.J.1
Marais, A.D.2
Tanyanyiwa, D.M.3
Burnett, J.R.4
-
19
-
-
84870478439
-
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
-
Giugliano RP, Desai NR, Kohli P, et al; LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012; 380:2007-2017
-
(2012)
Lancet
, vol.380
, pp. 2007-2017
-
-
Giugliano, R.P.1
Desai, N.R.2
Kohli, P.3
-
20
-
-
84871326497
-
Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial
-
Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308:2497-2506
-
(2012)
JAMA
, vol.308
, pp. 2497-2506
-
-
Sullivan, D.1
Olsson, A.G.2
Scott, R.3
-
21
-
-
84869220345
-
Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial
-
Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012; 126:2408-2417
-
(2012)
Circulation
, vol.126
, pp. 2408-2417
-
-
Raal, F.1
Scott, R.2
Somaratne, R.3
-
22
-
-
84926206074
-
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
-
Sabatine MS, Giugliano RP, Wiviott SD, et al; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1500-1509
-
(2015)
N Engl J Med
, vol.372
, pp. 1500-1509
-
-
Sabatine, M.S.1
Giugliano, R.P.2
Wiviott, S.D.3
|